Sidley advised CanSino Biologics Inc. (HKEX: 6185) as the Hong Kong and U.S. counsel in its HK$1.25 billion (approximately US$160.5 million) global offering and listing of H-Shares on the Main Board of the Stock Exchange of Hong Kong Limited. Morgan Stanley Asia Limited and CLSA Capital Markets Limited acted as joint sponsors in this transaction.
CanSino Biologics Inc. is a bio-tech leader in research and development, manufacturing and commercialization of vaccine products for human use in China.
The Sidley team was led by partners Mengyu Lu and Kefei Li, with support from senior counsel Chen Yang, associates Angela Zhang and Samantha Peng, and China advisors Guanlin Wang and Rock Liu. Legal managers Jenny Han and Ying Liu and legal assistants Junyi Li and Meiyi Li also provided assistance.
Sidley leads the Hong Kong legal adviser league table on deal counts in 2018.*
*RyanBen Capital data 2018.